PE91198A1 - DERIVADOS PIRIDO[3,4-d]PIRIMIDINA - Google Patents

DERIVADOS PIRIDO[3,4-d]PIRIMIDINA

Info

Publication number
PE91198A1
PE91198A1 PE1997000611A PE00061197A PE91198A1 PE 91198 A1 PE91198 A1 PE 91198A1 PE 1997000611 A PE1997000611 A PE 1997000611A PE 00061197 A PE00061197 A PE 00061197A PE 91198 A1 PE91198 A1 PE 91198A1
Authority
PE
Peru
Prior art keywords
compounds
halogen
erb
preference
alkyl
Prior art date
Application number
PE1997000611A
Other languages
English (en)
Spanish (es)
Inventor
Malcolm Clive Carter
Stephen Barry Guntrip
George Stuart Cockerill
Kathryn Jane Smith
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614763.2A external-priority patent/GB9614763D0/en
Priority claimed from GBGB9625492.5A external-priority patent/GB9625492D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE91198A1 publication Critical patent/PE91198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE1997000611A 1996-07-13 1997-07-11 DERIVADOS PIRIDO[3,4-d]PIRIMIDINA PE91198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614763.2A GB9614763D0 (en) 1996-07-13 1996-07-13 Heterocyclic compounds
GBGB9625492.5A GB9625492D0 (en) 1996-12-07 1996-12-07 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
PE91198A1 true PE91198A1 (es) 1999-01-15

Family

ID=26309694

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000611A PE91198A1 (es) 1996-07-13 1997-07-11 DERIVADOS PIRIDO[3,4-d]PIRIMIDINA

Country Status (25)

Country Link
US (2) US6174889B1 (cg-RX-API-DMAC7.html)
EP (2) EP0912570B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000514445A (cg-RX-API-DMAC7.html)
KR (1) KR20000023812A (cg-RX-API-DMAC7.html)
CN (1) CN1230187A (cg-RX-API-DMAC7.html)
AP (1) AP9901434A0 (cg-RX-API-DMAC7.html)
AR (1) AR007856A1 (cg-RX-API-DMAC7.html)
AT (1) ATE249458T1 (cg-RX-API-DMAC7.html)
AU (1) AU3443997A (cg-RX-API-DMAC7.html)
BR (1) BR9710359A (cg-RX-API-DMAC7.html)
CA (1) CA2260061A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ8999A3 (cg-RX-API-DMAC7.html)
DE (1) DE69724789T2 (cg-RX-API-DMAC7.html)
EA (1) EA199900022A1 (cg-RX-API-DMAC7.html)
ES (1) ES2206729T3 (cg-RX-API-DMAC7.html)
HR (1) HRP970371A2 (cg-RX-API-DMAC7.html)
ID (1) ID19403A (cg-RX-API-DMAC7.html)
IL (1) IL127796A0 (cg-RX-API-DMAC7.html)
IS (1) IS4939A (cg-RX-API-DMAC7.html)
NO (1) NO990124L (cg-RX-API-DMAC7.html)
PE (1) PE91198A1 (cg-RX-API-DMAC7.html)
PL (1) PL331221A1 (cg-RX-API-DMAC7.html)
TR (1) TR199900049T2 (cg-RX-API-DMAC7.html)
WO (1) WO1998002438A1 (cg-RX-API-DMAC7.html)
YU (1) YU1099A (cg-RX-API-DMAC7.html)

Families Citing this family (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
HRP20000286A2 (en) 1997-11-11 2000-12-31 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ20004727A3 (cs) 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
KR100736502B1 (ko) 1998-09-29 2007-07-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환된 3-시아노퀴놀린
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
PT1117659E (pt) * 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
ES2295035T3 (es) 1999-07-09 2008-04-16 Glaxo Group Limited Anilinoquinazolinas como inhibidores de proteina tirosina quinasa.
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
DE60029007T2 (de) 1999-11-05 2007-01-11 Astrazeneca Ab Quinazolin-derivate als vegf-hemmer
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
WO2001042246A2 (en) 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
JP2003518123A (ja) 1999-12-21 2003-06-03 スージェン・インコーポレーテッド ４−置換７−アザ−インドリン−２−オンおよびその蛋白質キナーゼ阻害剤としての使用
EP1294724B1 (en) 2000-06-26 2006-04-19 Pfizer Products Inc. Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents
US7157466B2 (en) * 2000-06-30 2007-01-02 Smithkline Beecham (Cork) Limited Quinazoline ditosylate salt compounds
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
EP1311500A2 (en) * 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE60212487T2 (de) * 2001-04-13 2006-12-21 Pfizer Products Inc., Groton Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003074529A2 (en) 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
EP1492568A1 (en) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20050239784A1 (en) * 2002-07-15 2005-10-27 Lacrampe Jean F A 3-Phenyl analogs of toxoflavine as kinase inhibitors
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2004033446A1 (en) * 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003291394B2 (en) 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2507392A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
US20040156869A1 (en) * 2002-12-13 2004-08-12 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues
MXPA05006676A (es) 2002-12-19 2005-08-16 Pfizer Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
DK1625121T3 (da) 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidinderivater til behandling af abnorm cellevækst
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
CA2525969A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US20070105865A1 (en) * 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2005120509A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
HRP20100298T1 (hr) 2004-08-26 2010-06-30 Pfizer Inc. Enantiomerno čisti aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
CN101124228B (zh) 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
NZ562453A (en) 2005-03-31 2010-04-30 Agensys Inc Antibodies and related molecules that bind to 161P2F10B proteins
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AU2006261607A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
AP2013006963A0 (en) 2005-09-07 2013-07-31 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like Kinase-1
ATE488513T1 (de) 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
DK1926996T3 (da) 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
BRPI0708034A2 (pt) 2006-02-10 2011-05-17 Transtech Pharma Inc derivados benzazol, composições e métodos de uso como inibidores aurora quinase
JP2009527479A (ja) * 2006-02-17 2009-07-30 アバロン ファーマシューティカルズ，インコーポレイテッド ヒドロキシピペリジン誘導体とその使用
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR100760148B1 (ko) 2006-07-19 2007-09-18 주식회사 엘지생활건강 알파-리포산을 안정화시킨 화장료 조성물
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
WO2008016123A1 (en) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008067119A2 (en) * 2006-11-27 2008-06-05 Smithkline Beecham Corporation Novel compounds
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8637531B2 (en) * 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
US8143394B2 (en) * 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CA2684470C (en) * 2007-04-16 2016-02-09 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
KR101132880B1 (ko) 2007-04-18 2012-06-28 화이자 프로덕츠 인크. 비정상적인 세포 성장의 치료를 위한 술포닐 아미드 유도체
JP2010527915A (ja) * 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
MX2009012117A (es) * 2007-05-09 2009-11-23 Pfizer Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos.
WO2009033094A2 (en) 2007-09-07 2009-03-12 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
CN101878203A (zh) 2007-10-29 2010-11-03 纳科法尔马有限公司 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2225226B1 (en) * 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
AU2009240643B2 (en) * 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8536187B2 (en) * 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2330909B1 (en) * 2008-08-12 2013-09-18 GlaxoSmithKline LLC Chemical compounds
EP2384326B1 (en) 2008-08-20 2014-04-23 Zoetis LLC Pyrrolo[2,3-d]pyrimidine compounds
US7737157B2 (en) * 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
TW201016704A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with RAS gene mutation
WO2010036928A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
CN101735200B (zh) * 2008-11-17 2013-01-02 岑均达 喹唑啉类化合物
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
BR112012000735A2 (pt) 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
KR20120105423A (ko) 2009-09-11 2012-09-25 제넨테크, 인크. 항암제에 반응할 증가된 가능성을 갖는 환자를 확인하는 방법
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
PT2534153T (pt) 2010-02-12 2016-12-27 Pfizer Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AU2011268356B2 (en) 2010-06-16 2013-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
CN105061438B (zh) 2010-06-23 2017-07-04 韩美科学株式会社 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
MX2013000676A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
MX2013000667A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
EP2596026B1 (en) 2010-07-23 2020-04-08 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
CA2845179A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
EP3275902A1 (en) 2011-10-04 2018-01-31 IGEM Therapeutics Limited Ige anti-hmw-maa antibody
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
HUE044558T2 (hu) 2013-03-14 2019-11-28 Tolero Pharmaceuticals Inc JAK és ALK2 inhibitorok és eljárások alkalmazásukra
EP2970211B1 (en) * 2013-03-15 2017-07-26 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
EP4012049A3 (en) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to mek/erk inhibitors
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
PE20161436A1 (es) 2014-04-30 2017-01-08 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271B1 (en) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
MY188938A (en) 2014-12-24 2022-01-13 Genentech Inc Therapeutic, diagnostic and prognostic methods for cancer of the bladder
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
MX382566B (es) 2015-05-01 2025-03-13 Univ Emory Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
KR20180100125A (ko) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. Mtap 널 암을 치료하기 위한 mat2a 억제제
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
JP7150823B2 (ja) 2017-09-08 2022-10-11 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
WO2020061101A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
EP3898592B1 (en) 2018-12-20 2024-10-09 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
EP3898616B1 (en) 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
PH12021552922A1 (en) 2019-05-21 2022-04-04 Amgen Inc Solid state forms
EP4007752B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
JP7756070B2 (ja) 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
KR20220109408A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
CN115873067A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
EP4054720A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
EP4620531A3 (en) 2019-11-08 2025-11-26 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
MX2022005726A (es) 2019-11-14 2022-06-09 Amgen Inc Sintesis mejorada del compuesto inhibidor de g12c de kras.
KR20220101125A (ko) 2019-11-14 2022-07-19 암젠 인크 Kras g12c 억제제 화합물의 개선된 합성
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
BR112023022819A2 (pt) 2021-05-05 2024-01-16 Revolution Medicines Inc Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
CR20250141A (es) 2022-10-14 2025-05-26 Black Diamond Therapeutics Inc Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024253668A1 (en) 2023-04-07 2025-11-13 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5600M (cg-RX-API-DMAC7.html) * 1966-07-19 1968-01-08
EP0597845A1 (en) * 1990-05-25 1994-05-25 Georgetown University GROWTH FACTOR WHICH INHIBITS THE GROWTH OF CELLS OVEREXPRESSING THE HUMAN ONCOGENE erbB-2
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (cg-RX-API-DMAC7.html) 1994-11-12 1997-12-01 Zeneca Ltd
NZ296456A (en) 1994-11-14 1999-09-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines; inhibition of protein tyrosine kinase mediated cellular proliferation
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA000072B1 (ru) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента
WO1998002437A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
US6413971B1 (en) * 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives

Also Published As

Publication number Publication date
US6723726B1 (en) 2004-04-20
HRP970371A2 (en) 1998-08-31
TR199900049T2 (xx) 1999-04-21
ATE249458T1 (de) 2003-09-15
ID19403A (id) 1998-07-09
ES2206729T3 (es) 2004-05-16
YU1099A (en) 1999-11-22
CZ8999A3 (cs) 1999-06-16
KR20000023812A (ko) 2000-04-25
EP1304110A2 (en) 2003-04-23
AU3443997A (en) 1998-02-09
PL331221A1 (en) 1999-07-05
AR007856A1 (es) 1999-11-24
AP9901434A0 (en) 1999-03-31
DE69724789D1 (de) 2003-10-16
EA199900022A1 (ru) 1999-08-26
BR9710359A (pt) 1999-08-17
IS4939A (is) 1998-12-31
CN1230187A (zh) 1999-09-29
CA2260061A1 (en) 1998-01-22
NO990124L (no) 1999-03-11
NO990124D0 (no) 1999-01-12
EP0912570A1 (en) 1999-05-06
IL127796A0 (en) 1999-10-28
JP2000514445A (ja) 2000-10-31
WO1998002438A1 (en) 1998-01-22
US6174889B1 (en) 2001-01-16
EP1304110A3 (en) 2003-12-17
EP0912570B1 (en) 2003-09-10
DE69724789T2 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
PE91198A1 (es) DERIVADOS PIRIDO[3,4-d]PIRIMIDINA
PE91098A1 (es) DERIVADOS DE PIRIDO[3,4-d]PIRIMIDINA
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
BRPI0410720A (pt) quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
PE20030759A1 (es) Uso de ureas de benzotiazoles
BR9916590A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
BR0014973A (pt) Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
EA200101203A1 (ru) Производные пурина
ES2033316T3 (es) Procedimiento para preparar derivados de 4-aminoquinolina.
AR004320A1 (es) Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa.
EA200200770A1 (ru) Производные пурина
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
BR0007424A (pt) Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto
ES529150A0 (es) Metodo de preparar derivados de oxadiazolil-imidazo (1, 4) benzodiazepina
ES8802517A1 (es) Un procedimiento para preparar fenoxialquil (substituido con heterocido)-isoxazoles y furanos.
BR9809491A (pt) "derivados de ergolina e seu uso como antagonista de receptor de somatostatina"
BR0309463A (pt) Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
Saxena et al. Synthesis and antiviral activity of certain 4-substituted and 2, 4-disubstituted 7-[(2-hydroxyethoxy) methyl] pyrrolo [2, 3-d] pyrimidines
TR199900503T2 (xx) 3-�kameli pirido $4',3':4,5]thieno $2,3-D] pirimidin-t�revleri, elde edili�leri ve kullan�mlar�.
ES2183866T3 (es) Derivados de beta-aril y beta-heteroaril-alfa-cianoacrilamidas sustituido como inhibidors de la tirosina quinasa.
ES8705436A1 (es) Un procedimiento para la obtencion de derivados de bi- y triciclicosdde piridona
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.

Legal Events

Date Code Title Description
FX Voluntary withdrawal